PMID- 25381980
OWN - NLM
STAT- MEDLINE
DCOM- 20150701
LR  - 20220330
IS  - 1098-2299 (Electronic)
IS  - 0272-4391 (Linking)
VI  - 75 Suppl 1
DP  - 2014 Nov
TI  - Emergence of antinuclear antibodies in psoriatic patients treated with 
      infliximab: personal experience and literature review.
PG  - S61-3
LID - 10.1002/ddr.21198 [doi]
AB  - Psoriasis is a chronic inflammatory skin disease affecting up to 2.5% of the 
      population, with joint involvement in approximately 30% of patients. Given the 
      role of tumor necrosis factor (TNF) in the pathogenesis of psoriasis, anti-TNF 
      therapies have been developed; several studies have demonstrated the efficacy of 
      infliximab (IFX) as induction and maintenance therapy in the treatment of 
      moderate to severe plaque psoriasis. The development of antinuclear antibodies 
      (ANA) in anti-TNF-treated patients has been frequently reported. The aim of this 
      study was to investigate the incidence of ANA and anti-double stranded DNA 
      (anti-dsDNA) antibodies in psoriatic patients receiving IFX. Incidence of new ANA 
      and anti-ds-DNA was 16.2% and 8.1% respectively. No case of anti-TNF induced 
      Lupus was observed during the follow-up.
CI  - (c) 2014 Wiley Periodicals, Inc.
FAU - Chimenti, Maria Sole
AU  - Chimenti MS
AD  - Dipartimento di "Medicina dei Sistemi"-Reumatologia, Allergologia e Immunologia 
      Clinica, Universita di Rome "Tor Vergata", 00163, Rome, Italy.
FAU - Spinelli, Francesca Romana
AU  - Spinelli FR
FAU - Giunta, Alessandro
AU  - Giunta A
FAU - Martinelli, Francesco
AU  - Martinelli F
FAU - Saraceno, Rosita
AU  - Saraceno R
FAU - Conti, Fabrizio
AU  - Conti F
FAU - Perricone, Roberto
AU  - Perricone R
FAU - Valesini, Guido
AU  - Valesini G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Drug Dev Res
JT  - Drug development research
JID - 8204468
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Antinuclear/*immunology
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunoglobulin M/immunology
MH  - Infliximab
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy/*immunology
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
OTO - NOTNLM
OT  - anti-TNF
OT  - anti-nuclear-antibodies
OT  - disease activity
OT  - psoriasis
EDAT- 2014/11/11 06:00
MHDA- 2015/07/02 06:00
CRDT- 2014/11/11 06:00
PHST- 2014/11/11 06:00 [entrez]
PHST- 2014/11/11 06:00 [pubmed]
PHST- 2015/07/02 06:00 [medline]
AID - 10.1002/ddr.21198 [doi]
PST - ppublish
SO  - Drug Dev Res. 2014 Nov;75 Suppl 1:S61-3. doi: 10.1002/ddr.21198.